Orchid Pharma Signs $80M Latin America Licensing Deal for Exblifep
Orchid Pharma Ltd 路 Press Release 路 24 Oct 2026, 10:33 pm
Orchid Pharma Signs $80M Latin America Licensing Deal for Exblifep Orchid Pharma Ltd. entered a licensing and supply agreement on 24th Oct'26 with Laboratorio Libra S.A. to expand its novel antibiotic Exblifep across nine Latin American markets, including Chile, Costa Rica, Ecuador, and Uruguay. Orchid will manufacture and supply finished dosage forms, while Libra holds exclusive registration, import, and marketing rights. The 10-year partnership presents an estimated $80 million commercial opportunity based on projected regional demand. Commercial rollouts remain subject to local regulatory approvals.
Original exchange filing (PDF)
More announcements from Orchid Pharma Ltd
- Audio Recording of the Analysts/Investors Earnings Call - Orchid Pharma Limited ('the Company') 路 18 Nov 2026
- Board Comments on fine levied by Stock Exchanges 路 17 Nov 2026
- Investor Presentation-Quarter II of FY 2026-27, ended on September 30, 2026 路 17 Nov 2026
- Statement of deviation or variation for the quarter ended on September 30, 2026 on the use of proceeds of funds raised through Qualified institutional placement (QIP) 路 14 Nov 2026
- Declaration of Financial results for quarter and half year ended on September 30, 2026 路 14 Nov 2026
- Outcome of Board Meeting 路 14 Nov 2026
- Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 14 Nov 2026
- Monitoring Agency Report for the Quarter-II ended on September 30, 2026 路 14 Nov 2026
